共查询到17条相似文献,搜索用时 187 毫秒
1.
综述:2型糖尿病与轻度认知障碍 总被引:1,自引:0,他引:1
阿尔茨海默病(Alzheimer's disease,AD)是一个连续的病理生理过程,包括轻度认知障碍前期(pre-MCI)、轻度认知障碍期(mild cognitive impairment,MCI)和痴呆期.AD临床期病程不可逆转,因此,pre-MCI和MCI的早期发现和干预就成为延缓和逆转AD发生的重要环节.大量研究表明,2型糖尿病(T2DM)胰岛素抵抗是导致MCI和AD的独立危险因素,T2DM与AD及AD前期认知功能障碍有密切关系.本文重点综述2型糖尿病与MCI及AD之间的相关性,探讨2型糖尿病治疗对AD的发生进行有效干预的可能性,为AD早期发现和临床治疗提供新线索. 相似文献
2.
3.
4.
轻度认知障碍(mild cognitive impairment,MCI)是介于正常老化和痴呆之间的过渡阶段,MCI患者是阿尔茨海默病(Alzheimer's disease,AD)的风险人群.本文介绍了国际上MCI诊断标准及其变化和修订,提出了理想的诊断模型.根据国内外研究,从认知和精神行为两个方面综述了MCI的神经心理损伤特征及其相应的诊断工具,简要回顾了现有针对MCI开展干预的各种方法.指出早期识别和干预研究需要从实验室小样本扩展到社区大样本老年人群,从横断研究扩展到纵向追踪,综合采用多种识别指标,并结合多种干预方法以达到最优效果. 相似文献
5.
阿尔茨海默病(Alzheimer's disease,AD)是发生于老年和老年前期、以进行性认知功能障碍和行为异常为特征的中枢神经系统退行性疾病,是老年痴呆中最常见类型。轻度认知功能障碍(mild cognitive impairment,MCI)是介于正常衰老和痴呆之间的一种中间状态,指有轻度的记忆或认知损伤,但尚未达到痴呆程度的一种状态,日常生活和社会功能不受影响,其中很大一部分患者最终进展为AD。临床诊断AD患者多已达中晚期,为了能早期诊断AD及预测MCI的转归,有关AD的生物学标注物的研究成为近年来的科研热点。AD患者颅脑的大体病理特征为脑萎缩,其萎缩有别于正常老龄化所致的退行性改变,有其自身特点,这种特定形式的萎缩有可能成为AD早期诊断的生物学标志物。基于体素的形态测量学(voxel-based morphometry,VBM)是一种基于像素水平对脑核磁图像进行自动、全面、客观分析的技术,可以定量分析全脑结构、刻画出局部脑区结构特征,是一种较好的脑形态分析工具,广泛用于阿尔茨海默病及轻度认知功能障碍的研究中,本文综述了近年来其研究进展,期望为临床及科研提供参考。 相似文献
6.
7.
阿尔茨海默病(Alzheimer's disease,AD)是一种常见的神经退行性疾病,以胞外淀粉样蛋白(amyloid-β,Aβ)沉积和胞内神经纤维缠结为主要病理特征.AD发病机理尚未完全探明,并且缺乏有效的早期临床诊断方法,AD患者往往在轻度认知障碍(mild cognitive impairment,MCI)和痴... 相似文献
8.
树突棘和突触的病理改变在认知功能障碍发病机制中具有十分重要的作用,研究表明大脑发育调节蛋白(developmentregulationbrainprotein,Drebrin)能够调节树突棘和突触的形态和重塑。Drebrin的减少可能通过树突棘内细胞骨架变化,使树突棘的形态结构受到影响,导致突触功能和结构的变化。但目前阿尔茨海默病(Alzheimer’Sdisease,AD)脑内突触病理变化的具体机制及Drebrin和突触之间的关系仍不明确。探讨Drebrin与认知功能的关系及其机制,对临床上早期干预认知功能障碍、寻找AD的有效诊断治疗措施具有重要意义。 相似文献
9.
认知障碍是一种主要影响认知能力(包括学习、记忆、感知和问题解决等)的心理健康障碍。认知障碍常见于阿尔茨海默病、血管性痴呆、轻度认知障碍等患者。与药物治疗相比,针灸治疗具有低成本、可耐受性和安全等特点,已成为改善认知功能的潜在工具。许多研究表明,在认知障碍的患者中,针灸治疗具有明显改善认知功能的作用。但针灸改善认知功能的机制仍不清楚。基于中医从肠治脑的理论基础以及目前实验研究,脑-肠轴与针灸改善大脑认知功能关系密切。对于针灸改善认知的脑-肠轴机制的理解能促进肠道微生物微观机制研究,但肠道微生物存在个体差异、动态变化、种类繁多等特征,以肠道稳态为调控目标的新针灸方案有待研究完善与规范。本文综述了针灸干预脑-肠轴治疗认知障碍,针灸通过维持肠道生态平衡、保持肠道菌群多样性、调整有益菌群丰度、调节代谢、促进生成脑源性神经营养因子(BDNF)、抑制小胶质细胞激活、降低神经炎症反应、减少Aβ蛋白沉积等机制,实现对认知障碍的治疗。 相似文献
10.
11.
The concept of mild cognitive impairment (MCI) identifies persons who are neither cognitively normal nor demented. There is increasing evidence that MCI defines a group of persons who are at near-term risk of developing dementia and particularly Alzheimer''s disease (AD). MCI thus constitutes an attractive target population for preventive treatments of AD. MCI is associated with aging and is more prevalent than dementia. There are several clinical and biological markers that are predictive of MCI prognosis, including depressive symptoms, cognitive deficits, brain imaging and neurochemical findings. The clinician needs to be especially alert to depressive and other mood symptoms which are common in MCI and potentially treatable. Trials of current medications for prevention of MCI progression to dementia have been largely negative. There are observational data suggesting that lifestyle modifications including exercise, leisure activities, cognitive stimulation, and social activities may be effective for prevention of MCI progression. There are many novel therapies currently in trials for early AD, and if effective they may prove to be helpful in prevention of MCI progression as well. 相似文献
12.
《Médecine Nucléaire》2007,31(6):294-301
The concept of mild cognitive impairment, MCI, has been proposed by Petersen and described like a state between the cognitive changes of normal aging and very early dementia. However, MCI appears to be a heterogeneous clinical syndrome in term of etiological factors, clinical patterns or clinical course. New criteria of MCI are proposed for use in clinical research. Identification of patients at risk for Alzheimer disease, AD, is an important goal. Ongoing clinical and neuroimaging (magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT),18F flouorodeoxyglucose-photo emission tomography (FDG-PET)) studies are focusing on the identification of those individuals with mild cognitive impairment (MCI) who are most likely to convert to AD. 相似文献
13.
The risk for Alzheimer's disease (AD) is associated with lifestyle factors, especially cigarette smoking. In this study we investigated the influence of smoking on the serum levels of folic acid, LDL and HDL in AD patients, patients with minimal cognitive impairment (MCI) and patients with major depression. We investigated a total of n = 374 patients in the diagnostic categories:, AD: n = 272, MCI: n = 60, Major depression: n = 42. We found significantly lower HDL levels in smokers and previous smokers in comparison to non-smokers, p<0,05. The LDL: HDL ratio in smokers was significant higher (+20%) compared to previous smokers and non-smokers, p < 0.05. The mean levels of folic acid were statistically significant (p<0.05) lower (-24%) in smokers compared to non-smokers. Patients with MCI and Alzheimer;s disease (and also major depression) who are "smokers" show serum levels of HDL and folic acid that are known to be strong risk factors for vascular damage and increased risk for vascular brain damage and impaired cognitive function. Therefore cessation of smoking, substitution with folate or statin therapy of smoking patients with MCI or AD might be beneficial to slow down further cognitive decline. 相似文献
14.
Atrophy of the cortical thickness and gray matter volume are regarded as sensitive markers for the early clinical diagnosis of Alzheimer’s disease (AD). This study aimed to investigate differences in atrophy patterns in the frontal-subcortical circuits between MCI and AD, assess whether these differences were essential for the pathologic basis of cognitive impairment. A total of 131 individuals were recruited, including 45 with cognitively normal controls (CN), 46 with MCI, and 40 with AD. FreeSurfer software was used to perform volumetric measurements of the frontal-subcortical circuits from 3.0T magnetic resonance (MR) scans. Data revealed that both MCI and AD subjects had a thinner cortex in the left caudal middle frontal gyrus and the left lateral orbitofrontal gyrus compared with CN individuals. The left lateral orbitofrontal gyrus was also thinner in AD compared with MCI patients. There were no statistically significant differences in the cortical mean curvature among the three groups. Both MCI and AD subjects exhibited smaller bilateral hippocampus volumes compared with CN individuals. The volumes of the bilateral hippocampus and the right putamen were also smaller in AD compared with MCI patients. Logistic regression analyses revealed that the left lateral orbitofrontal gyrus and bilateral hippocampus were risk factors for cognitive impairment. These current results suggest that atrophy was heterogeneous in subregions of the frontal-subcortical circuits in MCI and AD patients. Among these subregions, the reduced thickness of the left lateral orbitofrontal and the smaller volume of the bilateral hippocampus seemed to be markers for predicting cognitive impairment. 相似文献
15.
Dominic Holland Linda K. McEvoy Rahul S. Desikan Anders M. Dale for the Alzheimer’s Disease Neuroimaging Initiative 《PloS one》2012,7(10)
The tau and amyloid pathobiological processes underlying Alzheimer disease (AD) progresses slowly over periods of decades before clinical manifestation as mild cognitive impairment (MCI), then more rapidly to dementia, and eventually to end-stage organ failure. The failure of clinical trials of candidate disease modifying therapies to slow disease progression in patients already diagnosed with early AD has led to increased interest in exploring the possibility of early intervention and prevention trials, targeting MCI and cognitively healthy (HC) populations. Here, we stratify MCI individuals based on cerebrospinal fluid (CSF) biomarkers and structural atrophy risk factors for the disease. We also stratify HC individuals into risk groups on the basis of CSF biomarkers for the two hallmark AD pathologies. Results show that the broad category of MCI can be decomposed into subsets of individuals with significantly different average regional atrophy rates. By thus selectively identifying individuals, combinations of these biomarkers and risk factors could enable significant reductions in sample size requirements for clinical trials of investigational AD-modifying therapies, and provide stratification mechanisms to more finely assess response to therapy. Power is sufficiently high that detecting efficacy in MCI cohorts should not be a limiting factor in AD therapeutics research. In contrast, we show that sample size estimates for clinical trials aimed at the preclinical stage of the disorder (HCs with evidence of AD pathology) are prohibitively large. Longer natural history studies are needed to inform design of trials aimed at the presymptomatic stage. 相似文献
16.
Objectively diagnosing age‐related cognitive impairment (ACI), mild cognitive impairment (MCI), and early‐stage Alzheimer''s disease (AD) is a difficult task, as most cognitive impairment is clinically established via questionnaires, history, and physical examinations. A recent study has suggested that monitoring a miRNA triad, miR‐181a‐5p, miR‐146a‐5p, and miR‐148a‐3p can identify ACI and its progression to MCI and AD (Islam et al., EMBO Mol Med. 13: e14997, 2021). This commentary deliberates findings from this article, such as elevated levels of the miRNA triad in the brain impairing neural plasticity and cognitive function, the efficiency of measuring the miRNA triad in the circulating blood diagnosing MCI and AD, and the promise for improving cognitive function in MCI and AD by inhibiting this miRNA triad. Additional studies required prior to employing this miRNA triad in clinical practice are also discussed. 相似文献
17.
Steffen Wolfsgruber Michael Wagner Klaus Schmidtke Lutz Fr?lich Alexander Kurz Stefanie Schulz Harald Hampel Isabella Heuser Oliver Peters Friedel M. Reischies Holger Jahn Christian Luckhaus Michael Hüll Hermann-Josef Gertz Johannes Schr?der Johannes Pantel Otto Rienhoff Eckart Rüther Fritz Henn Jens Wiltfang Wolfgang Maier Johannes Kornhuber Frank Jessen 《PloS one》2014,9(7)